These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17516109)

  • 1. Significance of CD44 expression in gastrointestinal stromal tumors in relation to disease progression and survival.
    Hsu KH; Tsai HW; Shan YS; Lin PW
    World J Surg; 2007 Jul; 31(7):1438-44. PubMed ID: 17516109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implication and mitotic effect of CD44 cleavage in relation to osteopontin/CD44 interaction and dysregulated cell cycle protein in gastrointestinal stromal tumor.
    Hsu KH; Tsai HW; Lin PW; Hsu YS; Shan YS; Lu PJ
    Ann Surg Oncol; 2010 Aug; 17(8):2199-212. PubMed ID: 20146103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteopontin expression is an independent adverse prognostic factor in resectable gastrointestinal stromal tumor and its interaction with CD44 promotes tumor proliferation.
    Hsu KH; Tsai HW; Lin PW; Hsu YS; Shan YS; Lu PJ
    Ann Surg Oncol; 2010 Nov; 17(11):3043-52. PubMed ID: 20549562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis.
    Wang CJ; Zhang ZZ; Xu J; Wang M; Zhao WY; Tu L; Zhuang C; Liu Q; Shen YY; Cao H; Zhang ZG
    World J Gastroenterol; 2015 Jul; 21(27):8398-407. PubMed ID: 26217092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on associated biomarkers influencing recurrence, metastasis and prognosis in patients with gastrointestinal stromal tumors after complete resection].
    Fang YJ; Zhang RX; Luo RZ; Ou QJ; Wan DS; Pan ZZ; Wu XJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):242-6. PubMed ID: 23536344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
    Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
    Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of biologic potential and risk stratification for predicting disease-free survival after resection of primary gastrointestinal stromal tumor: A multivariate clinicopathological study.
    Vij M; Agrawal V; Kumar A; Pandey R
    Indian J Cancer; 2015; 52(3):351-7. PubMed ID: 26905135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of gastrointestinal stromal tumors.
    Bertin M; Angriman I; Scarpa M; Mencarelli R; Ranzato R; Ruffolo C; Polese L; Iacobone M; D'Amico DF
    Hepatogastroenterology; 2007; 54(73):124-8. PubMed ID: 17419245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
    Wu TJ; Lee LY; Yeh CN; Wu PY; Chao TC; Hwang TL; Jan YY; Chen MF
    BMC Gastroenterol; 2006 Oct; 6():29. PubMed ID: 17062131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria.
    Huang HY; Huang WW; Lin CN; Eng HL; Li SH; Li CF; Lu D; Yu SC; Hsiung CY
    Ann Surg Oncol; 2006 Dec; 13(12):1633-44. PubMed ID: 17013685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications.
    Sabah M; Cummins R; Leader M; Kay E
    Hum Pathol; 2006 Jun; 37(6):648-55. PubMed ID: 16733203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma.
    Kosunen A; Pirinen R; Ropponen K; Pukkila M; Kellokoski J; Virtaniemi J; Sironen R; Juhola M; Kumpulainen E; Johansson R; Nuutinen J; Kosma VM
    Oral Oncol; 2007 Jan; 43(1):51-9. PubMed ID: 16798062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors.
    Chou YP; Lin JW; Wang CC; Chiu YC; Huang CC; Chuah SK; Tai MH; Yi LN; Lee CM; Changchien CS; Hu TH
    Oncol Rep; 2008 Jan; 19(1):49-56. PubMed ID: 18097575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal mesenchymal tumors - from smooth muscle tumors to stromal tumors.
    Tai WC; Chuah SK; Lin JW; Chen HH; Huang HY; Kuo CM; Yi LN; Lee CM; Changchien CS; Hu TH
    Oncol Rep; 2008 Nov; 20(5):1157-64. PubMed ID: 18949416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
    Basilio-de-Oliveira RP; Pannain VL
    World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
    Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
    Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastrointestinal stromal tumors: clinicopathologic and survival evaluation in Rebagliati Hospital].
    Manrique MN; Soriano C; Yábar A; Frisancho O; Palacios AM
    Rev Gastroenterol Peru; 2012; 32(4):357-65. PubMed ID: 23307085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.